Matching slides 303,780
Current window 206,551-206,580
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

206,551-206,580 of 303,780

filter-aware
23
Data presented as Kaplan-Meier survival curves and tumor growth kinetics/bar charts.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
24
The diagram depicts a biological process flow involving iNKT cells, DCs, MDSCs, and inflammatory monocytes.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
25
The table uses checkmarks, crosses, and question marks to indicate performance/capability across different cell types.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
26
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
27
The slide presents clinical efficacy metrics (ORR, SD, mOS) and safety profile for iNKT cell therapy.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
29
The slide uses a process flow diagram to show trial progression and a list-based structure for clinical endpoints.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
30
The table displays patient characteristics (age, sex) and disposition (early discontinuation, death, progression) for three distinct dosing groups and the total population.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
31
The chart displays patient outcomes over time, with dots indicating progression and bars indicating stable disease.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
32
Includes a table of adverse events, box plots for cytokines (IL-1b, IL-6, CRP), and a longitudinal line chart for IFNy.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
33
The slide uses a staircase diagram to represent dose escalation levels.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
34
The slide presents a patient cohort table and a specific case study (Patient 6) showing M-spike protein and plasma cell levels over time.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
35
The slide presents clinical trial safety data including a table of adverse events and dot plots for inflammatory markers.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
36
Includes references to SITC #372 and NCT05108623.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Key Takeaways1 hit
38
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Key Takeaways1 hit
39
The slide uses a three-column layout to present distinct biological mechanisms supported by experimental data (line and bar charts).Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Key Takeaways1 hit
41
Illustrates the mechanism of action for two distinct therapeutic modalities.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
43
The slide uses a biological process diagram to explain the mechanism of action of the CARDIS platform.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
44
The slide uses a funnel metaphor to show the screening and selection process.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
45
The slide uses a funnel metaphor to show the progression from synthetic phage libraries to final candidates.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
47
The diagram shows the interaction between tumor cell receptors and iNKT cell receptors, including the secretion of IL15.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
48
Includes abstract number 358.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
49
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
50
The slide uses a Kaplan-Meier survival plot and longitudinal imaging to demonstrate therapeutic efficacy.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
51
The slide uses fluorescence microscopy images and an area chart to demonstrate the efficacy of the therapy.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
52
Includes abstract number 322.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
53
The slide uses a circular flow diagram to suggest a cycle of improvement or replacement of existing therapies.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
54
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
58
The slide uses a three-column layout to explain the discovery, mechanism of action, and manufacturing scalability of the MiNK-413 therapy.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
61
The slide outlines a three-stage process: Cell expansion, Harvest & Purification, and Formulating & Fill/Finish.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
62
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit